140 related articles for article (PubMed ID: 16490802)
1. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment.
Peng JZ; Pulido F; Causemaker SJ; Li J; Lorenzo A; Cepeda C; García Cabanillas JA; DaSilva B; Brun SC; Arribas J
J Clin Pharmacol; 2006 Mar; 46(3):265-74. PubMed ID: 16490802
[TBL] [Abstract][Full Text] [Related]
2. Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.
Moltó J; Valle M; Blanco A; Negredo E; DelaVarga M; Miranda C; Miranda J; Domingo P; Vilaró J; Tural C; Costa J; Barbanoj MJ; Clotet B
Clin Pharmacokinet; 2007; 46(1):85-92. PubMed ID: 17201460
[TBL] [Abstract][Full Text] [Related]
3. Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment.
Khaykin P; Kotzerke P; Stephan C; Nisius G; Bickel M; Haberl A; Stürmer M; Kurowski M; Brodt R; von Hentig N
Ther Drug Monit; 2014 Apr; 36(2):192-201. PubMed ID: 24632753
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S
Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
van der Lee M; Verweel G; de Groot R; Burger D
Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
[TBL] [Abstract][Full Text] [Related]
6. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
van der Lugt J; Lange J; Avihingsanon A; Ananworanich J; Sealoo S; Burger D; Gorowara M; Phanuphak P; Ruxrungtham K
Antivir Ther; 2009; 14(7):1001-4. PubMed ID: 19918104
[TBL] [Abstract][Full Text] [Related]
7. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
Seminari E; De Bona A; Gentilini G; Galli L; Schira G; Gianotti N; Uberti-Foppa C; Soldarini A; Dorigatti F; Lazzarin A; Castagna A
J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
[TBL] [Abstract][Full Text] [Related]
8. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.
Wyen C; Fuhr U; Frank D; Aarnoutse RE; Klaassen T; Lazar A; Seeringer A; Doroshyenko O; Kirchheiner JC; Abdulrazik F; Schmeisser N; Lehmann C; Hein W; Schömig E; Burger DM; Fätkenheuer G; Jetter A
Clin Pharmacol Ther; 2008 Jul; 84(1):75-82. PubMed ID: 18183034
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
[TBL] [Abstract][Full Text] [Related]
10. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
[TBL] [Abstract][Full Text] [Related]
11. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
[TBL] [Abstract][Full Text] [Related]
12. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
[TBL] [Abstract][Full Text] [Related]
13. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen.
Isaac A; Taylor S; Cane P; Smit E; Gibbons SE; White DJ; Drake SM; Khoo S; Back DJ
J Antimicrob Chemother; 2004 Aug; 54(2):498-502. PubMed ID: 15254024
[TBL] [Abstract][Full Text] [Related]
14. Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.
Micheli V; Regazzi M; Dickinson L; Meraviglia P; Villani P; Khoo SH; Viganò P; Cordier L; Cusato M; Duca P; Orlando G; Rizzardini G; Back DJ; Cargnel A
Ther Drug Monit; 2008 Jun; 30(3):306-13. PubMed ID: 18520602
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
van der Lee M; Sankatsing R; Schippers E; Vogel M; Fätkenheuer G; van der Ven A; Kroon F; Rockstroh J; Wyen C; Bäumer A; de Groot E; Koopmans P; Stroes E; Reiss P; Burger D
Antivir Ther; 2007; 12(7):1127-32. PubMed ID: 18018771
[TBL] [Abstract][Full Text] [Related]
17. Time-dependent interaction between lopinavir/ritonavir and fexofenadine.
van Heeswijk RP; Bourbeau M; Campbell P; Seguin I; Chauhan BM; Foster BC; Cameron DW
J Clin Pharmacol; 2006 Jul; 46(7):758-67. PubMed ID: 16809801
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients.
Canta F; Marrone R; Bonora S; D'Avolio A; Sciandra M; Sinicco A; De Rosa FG; Di Perri G
J Antimicrob Chemother; 2005 Feb; 55(2):280-1. PubMed ID: 15650005
[No Abstract] [Full Text] [Related]
19. Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir.
Hills-Nieminen C; Hughes CA; Houston S; Shafran SD
Ann Pharmacother; 2009 Dec; 43(12):2117-20. PubMed ID: 19934385
[TBL] [Abstract][Full Text] [Related]
20. Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil.
Vergara TR; Estrela RC; Suarez-Kurtz G; Schechter M; Cerbino-Neto J; Barroso PF
Ther Drug Monit; 2006 Apr; 28(2):175-9. PubMed ID: 16628127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]